Table 1.
Percentage growth inhibition results exerted by compounds 5a–e over the most sensitive cell lines.
| Cell Lines | Percentage Inhibition (at 10 μM) | |||||
|---|---|---|---|---|---|---|
| 5a | 5b | 5c | 5d | 5e | ||
| Leukemia | CCRF-CEM | 90.3 | 82.2 | |||
| HL-60(TB) | 86.1 | 106.9 | 93.7 | |||
| K-562 | 90.6 | 84.9 | 82.3 | |||
| MOLT-4 | 82.4 | 95.2 | 100.6 | |||
| RPMI-8226 | 80.6 | 87.9 | 90.8 | |||
| SR | 82.9 | 97.7 | 93.4 | |||
| NSCLC | A549/ATCC | 93.0 | ||||
| NCI-H23 | 96.0 | |||||
| NCI-H460 | 81.5 | |||||
| NCI-H522 | 90.7 | |||||
| Colon cancer | COLO 205 | 126.6 | 83.9 | |||
| HCC-2998 | 85.9 | 86.1 | ||||
| HCT-116 | 91.6 | 87.5 | 88.2 | 81.9 | ||
| HCT-15 | 85.2 | |||||
| HT29 | 94.3 | 90.2 | 90.8 | |||
| KM12 | ||||||
| SW-620 | 82.4 | |||||
| CNS cancer | SF-295 | 82.2 | ||||
| SF-539 | 98.7 | 84.9 | 81.1 | |||
| SNB-19 | 84.7 | |||||
| U251 | 88.7 | |||||
| Melanoma | MDA-MB-435 | 95.7 | 84.5 | |||
| SK-MEL-2 | 110.3 | |||||
| SK-MEL-28 | 90.6 | 81.3 | ||||
| SK-MEL-5 | 146.1 | 80.0 | 138.3 | 88.7 | ||
| UACC-62 | 95.3 | |||||
| Ovarian cancer | OVCAR-3 | 95.3 | ||||
| SK-OV-3 | 95.7 | |||||
| Renal Cancer | 786-0 | 108.7 | 84.4 | |||
| A498 | 136.2 | 90.9 | 85.7 | 93.6 | ||
| ACHN | 82.7 | |||||
| RXF 393 | 134.8 | |||||
| TK-10 | 83.5 | |||||
| UO-31 | 83.0 | |||||
| Prostate Cancer | PC-3 | 87.6 | 83.4 | |||
| Breast Cancer | MCF7 | 90.2 | 83.8 | 80.0 | ||
| MDA-MB-231/ATCC | 90.7 | 117.5 | 86.4 | |||
| HS 578T | 89.4 | |||||
| T-47D | 94.4 | 82.5 | ||||
| MDA-MB-468 | 116.6 | 87.4 | ||||
The bold figures indicate lethal effects in terms of percentage.